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ABSTRACT
THE DEVELOPMENT OF A
BIODEGRADABLE SCAFFOLD FOR A
TISSUE ENGINEERED HEART VALVE
by
Thomas Adam Alheidt
In the current state of medical technology, there exists the need for a quality
medical device to replace a failing heart valve. Presently, mechanical valves as
well as donor tissue valves, either from humans or animals are used to replace
failing heart valves. These valves although they can operate in the heart
satisfactorily are not equal to the body replacing its own valve. Tissue
Engineering in simple terms is the field of helping the body replace its own failing
organ. In scientific terms, Tissue Engineering is a relatively young field, a
majority of the major advancements have come in the last ten years. Currently,
work is feverishly being done to develop a tissue engineered heart valve both at
MIT and at the Harvard Medical School.
In this thesis, the author will detail a group of tissue engineering scaffolds
that were developed and tested which are comprised of biodegradable materials.
As the quantity of heart valve cells increases the polymer thickness needs to be
decreased, or degraded whereby keeping the overall heart valve thickness within
its physiological limitations. Also, in this thesis, the author will detail the initial and
then final solvent casting process used to develop the test samples. The first
process manufactured a three dimensional test sample whereas the final process
was used to develop two dimensional flat rectangular samples. These samples
produced from the final processing method showed promising results as well as
a manufacturing process capable of producing repeatable results with varying
compositions. Finally, the author will detail the recommended design and
development paths both with the material and the sample preparation process.
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CHAPTER 1
INTRODUCTION
"U.S. surgeons performed over 93,000 surgical heart valve repair and
replacement procedures in 2001 (about 300,000 were performed worldwide), yet
this market is still severely underserved." [Medtech
The heart valves being used in these procedures are both tissue and
mechanical. While it is widely accepted that they can prolong and improve a
patient's life, they are not the perfect replacement for a damaged valve. Patients
who have their heart valves replaced with either a mechanical or tissue valve
must endure a lifetime of drug regimens designed to keep their body from
degrading its function. "Artificial heart valves have been used clinically for nearly
four decades. In that time advances in our understanding of cardiac physiologic
features, biomechanics and materials science have consistently led to changes
in heart valve prosthetics." [Sapirsteinj] Where early experimental designs failed
in both animals and humans from a lack of biomaterial knowledge, now is no
longer an issue. "Blood flow through the valve is non-turbulent, and thus
hemolysis and stimulation of the clotting cascade are limited. Biocompatibility is
paramount: the blood contacting surfaces are not thrombogenic." [Sapirstein]
Doctors and engineers first inserted their design in the tricuspid valve, since the
pressure and flow rates are lower at that point than at the mitral valve.
The theoretical model proposed in this literature review is the development
of a biodegradable heart valve scaffold. The existing heart valves currently on the
1
2market will be reviewed from recent articles, for both mechanical and tissue
designs with references made to both positive and negative design aspects. The
proposed heart valve is to be created from a biodegradable scaffold
dimensionally equal to that of a human heart valve. Once the heart valve scaffold
has been created, it would then be inserted into a bioreactor. Once inside the
bioreactor endothelial growth will begin, coinciding with the degradation of the
polymeric scaffold. The articles reviewed in this paper support the decision made
on the overall design of the scaffold, with emphasis being the material structure
and composition. Listed in the literature review conclusion is a list of potential
scaffolds materials.
CHAPTER 2
LITERATURE REVIEW
2.1 Tissue valves
Tissue valves being used today represent the best mechanical substitute to the
original valve. A weakness of tissue valves, however, is that they have a short
lifespan. "Replacement of damaged heart valves with tissue valves has been a
clinical option since Ross and Barratt-Boyes first described aortic valve
replacement with a homograft in the early
1960s." [Sapirstein] Today there are four types
of tissue valves used in the United States: The
tri-leaflet valve, porcine heterografts, allograft,
and autografts. Only autograft valves do not
need to be treated with glutaraldehyde, a
chemical process used to sterilize and
strengthen the valve. Autograft valves don't need to be either imuno-supressed
or strengthened since they will be re-populated with native cells immediately
upon insertion, which does not occur with bovine, porcine, or Allograft tissue
valves. Tissue valves are chosen for their excellent flow parameters; however,
they have a much shorter life expectancy (7 to 10 years) as compared to
mechanical valves. While inside the body, the valve can fail due to complications
caused by calcification and or leaflet wear. After the valves (bovine or porcine)
3
4have been removed from the animal, they are cleaned and prepped, a ring is
attached to the bottom of the valve, and finally it is treated with glutaraldehyde.
As previously stated, tissue valves are treated with glutaraldehyde to
reduce the immune response, not eliminate it. Interestingly, in some cases
cellular attachment has been reported to both porcine and bovine tissue valves.
As with human valves, bovine and porcine heart valves, which are composed of
extracellular matrix proteins, can act as intrinsic templates for cellular
attachment, even when implanted into humans. "Therefore, various cell
extraction techniques are used to create decellularized tissues, including
chemical, enzymatic and mechanical methods of removing cellular components,
and leaving a material comprised primarily of extracellular matrix components."
[Schmidt]
A ring is attached to the valve, which could be composed of either a
polyester knit fabric or Dacron. The ring is used to give the surgeon an area to
suture the valve to the heart. During the development process, minor
modifications are made to the valve leaflets, since their excellent flow
characteristics are one of the primary reasons for their usage. At times, the
leaflets are supported with stents, to provide added strength. Bovine and porcine
valves have been used due to their close physiological composition to the human
heart valve.
Tissue valves in general have better hemodynamic qualities than
mechanical valves, which results in a lower rate of thrombus formation events.
"In order for materials to be transplanted to a patient from a donor, especially an
5animal donor, the tissue must be modified to increase resistance to degradation
and to decrease immunogenicity, while maintaining natural mechanical
properties." [Schmidt] Tissue valves used today are treated with glutaraldehyde,
"Glutaraldehyde-treated tissue exhibits altered mechanical properties compared
to untreated tissue. Porcine aortic valves crosslinked with glutaraldehyde tend to
be stiffer than fresh tissue and have stress relaxation rates about 60% of those
for fresh valves. Treated tissues also show increased apparent tensile
extensibility associated with shrinkage during fixation". [Schmidt] Glutaraldehyde
treatment of tissue valves has the following effects.
1. Suppress the immune response.
2. Increase the strength of the valve through cross-linking, most likely being
the collagen already present in the valve.
3. Enhance the materials resistance to enzymatic and or chemical
degradation.
4. Sterilize the material.
While this strengthening of the material and increased resistance to
physical degradation is advantageous glutaraldehyde treatment also prevevnts
the tissue from being repopulated with the patient's cells. "The major drawback to
bio-prostheses is the relatively high rate of structural deterioration that almost
uniformly occurs. Leaflet wear, exacerbated by calcification, leads to tears and
loss of adequate adaptation; clinically important valvular stenosis is less
common." [Sapirstein] A drawback from tissue valves is that when they are
treated with glutaraldehyde they tend to be more susceptible to degradation and
6are also prevented from being remodeled by the body. Cross-linking by
glutaraldehyde decreases the display of antigenic determinants by killing viable
tissue cells and by controlling the stability of the collagen triple helix. Data
collected thus far on tissue valves would suggest that, unless a method can be
developed to promote positive cellular growth on the valve after implantation, no
dramatic improvements will be made in this technology. A heart valve composed
from native tissue, unlike bovine, porcine, and allografts, has the ability to be
repopulated with a patient's own cells. This creates a more natural heart valve.
2.2 Tissue engineered valves
Over the past few years, researchers have created tissue scaffolds using
biodegradable polymers. These scaffolds are then seeded with endothelial cells.
After the cells have been seeded onto the scaffolds, they are placed in a
bioreactor for accelerated growth. Once the cell layer has grown to a sufficient
thickness, the valve is then implanted into the body. Once the tissue engineered
valve is implanted into the heart, it will immediately begin to adsorb proteins and
as time progresses, achieve proper endothelial attachment strength and
orientation. With acellular tissue, there is no need to treat the tissue chemically,
i.e. by glutaraldehyde, to suppress the patient's immune response. There is also
no need to physically reinforce the valve with stents so that it remains operational
during the numerous cyclic loads during the valve's lifespan. These valves are
the latest in heart valve technology. They offer the most promise since they
7would enjoy the benefits of both mechanical and tissue heart valves without
having any of their detriments.
The development of a tissue engineered heart valve has been hindered in
the past due to the lack of quality biomaterials. For a material to be successful as
a heart valve scaffold, it must be non-thrombogenic and have elastic and
physical properties similar to those of a native heart valve. One issue that needs
to be addressed is the following: tissue growth inside the bioreactor must be
comparable to natural tissue. Studies have shown that valves exposed to realistic
process parameters while inside a bioreactor do have equivalent physical
properties.
The dilemma occurs when it becomes apparent that the scaffold material
cannot withstand the arterial pressure of a native valve. Currently researchers
avoid this issue by using venous blood pressure to test their valves. In the
present medical technology field, there are several teams throughout the world
trying to develop varieties of heart valve scaffolds. If a heart valve scaffold is
going to be successful in the heart valve market, it must be grown under an
arterial pressure gradient. Tissue engineered heart valves only capable of
operating under venous pressure address a small fraction of the overall need.
Testing has been conducted in the field where a single acellular heart valve
leaflet was implanted into an existing animal valve while leaving the other two
leaflets intact. The other two leaflets thus served as controls in the experiment.
This procedure appears promising as a method for testing valve leaflet materials.
82.3 Mechanical valves
The introduction of the first mechanical heart valve occurred in 1952, when
Charles Hufnagel implanted his ball in cage mechanical heart valve. Mechanical
heart valves are defined by not having any living tissue anywhere in, or on the
device. There are currently three designs being marketed which are approved by
the FDA. Those designs are the following; ball in cage, tilting disc, and the bi-
leaflet design. The valves entered the market in the same order as they were
listed.
The first successfully marketed heart valve was the Star-Edwards caged
ball heart valve shown in Figure 2.2, a design similar to Hufnagel's and also
modeled after a design used by Ellis and
Bulbulian. The valve was developed in the
0950s, and clinically used for the first time in
August 25, 0960 during a human clinical trial.
When Starr and Edwards first began their
heart valve development, they were trying to
develop a valve that closely mimicked the
human heart valve. During this early development work, they attempted a design
with two leaflets that were composed of silicone rubber and were hinged to a
crossbar made of solid Teflon, which also had a Teflon cloth attached for fixation
purposes. "The leaflet valves were plagued by thrombus formation. Thrombus
would originate at the suture line and grow by direct extension onto the leaflets.
In most cases, the valve became totally occluded after only 2 or 3 days. After
Figure 2.3 Tilting disc heart valve, later
recalled from market due to catastrophic
failure.
9
months of work, Starr and Edwards abandoned the leaflet valve to go to a ball
valve." [Matthews]
The valve developed by Starr and Edwards and used during their initial
clinical trial remained essentially unchanged for many years to come. "It had a
methyl methacrylate (Lucite) cage with thick struts and a machined ring orifice. A
compression molded silicone rubber ball was placed inside the cage and the ring
was then solvent welded to the cage with acetone." [Matthews] In medical
device development terms it had a very quick development cycle "Lowell
Edwards determination and financial backing supported the provision of new
models for animal implantation every few weeks or months, allowing the
screening of a large number of designs in a short period of time." [Matthews] As
a precautionary step barium sulfate was embedded in the poppet, the barium
served to make the poppet radiopaque.
Additional design changes were attempted, however, the design
implemented during this initial clinical
trial and first marketed during the
1960's has been unchanged and
used successfully for over twenty
years. Although the Starr-Edwards
valve is not as heavily used now, as
it was in the past, it is estimated that
the valve has been inserted into more than 175,000 patients. The positives of
mechanical valves are listed below, however the biggest negative of a
10
mechanical heart valve is that the valves have a heavy shear rate, and unnatural
flow waves. Hence patients with mechanical heart valves need to be medicated
throughout their life to guard against thrombus formation. Table 2.1 lists
mechanical heart valves that have either been used in the past and or still being
used today. Each manufacturer listed in the table is divided into the following
three general design classifications: Ball Valves, Bi-Leaflet Disc Valves, and
Single Leaflet Valve. The following is a list of benefits that are attributable to
mechanical heart valves, but not enjoyed by Tissue Valves.
1. Mechanical valves can be mass-produced whereby controlling their material
composition and dimensions.
2. Valves are composed of bio-inert materials, whereby not creating an
adverse immune response from the body.
3. Materials used are of high strength, therefore can survive under extreme
cyclic loading.
4. Easily implant able
Table 2.1 Mechanical Valves
Ball Valves Bi-Leaflet Disc Valve Single Leaflet Valve
Starr Edwards valve St Jude Valve The Bjork Shiley valve
Magovern-Cromie
Sutureless Valve Medtronic Parallel Valve
Alliance Medical
Technologies Monostrut
Smeloff-Sutter Valve ATS Bileaflet Valve The Medtronic-Hall valve
Carbomedics Valve Omniscience valve
Edwards Duromedics Valve
During the 1970's, a new design was introduced to the market, the
"flapper" design, it consisted of a circular disk positioned within a metal ring and
then inserted inside a sewing cuff. This single leaflet valve design, refer to figure
2.3, decreased the size of the valve and also reduced the amount of
11
components, however, as time passed the design was shown to be inadequate.
"Mechanistically it functions like a native valve, permitting unimpeded forward
flow when open while preventing regurgitant flow when closed." [Sapirstein] The
valve did not operate very well while in the body after repeated operation, the
strut ended up separating from the rest of the valve, which then resulted in a disk
embolization. Following this catastrophic event, the valves were pulled from the
market. Attempts were made at improving the design, however, confidence in the
design was lost and it never regained its initial momentum. Several other designs
were developed that addressed this concern, either by having the struts
contiguous with the metal of the valve
ring (Technologies Monostrut) or a
Titanium shaft that passes through the
center of the disk, (Medtronic-Hall) or
where the disk operates by hinging
against the two sides of the ring,
',Omniscience valve). However, the
heart valve of choice currently is the bi-leaflet design by St. Jude Medical Inc.
This mechanical valve refer to figure 2.4, contains two semicircular disks of
pyrolytic carbon that open with independent hinge mechanisms. This design
provides the essential design characteristics needed from a mechanical heart
valve, long life (almost non-existent structural failures), non-thrombogenic, low
blood shear rate, and easy to install during surgery. The pyrolytic carbon valves
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are formed through a repetitive heating cycle that gives the material a smooth
strong surface resistant to thrombus formation.
Mechanical heart valves unlike tissue valves offer long term durability,
however, patients using them need life-long anticoagulation therapy, often suffer
from bleeding disorders, and the flow dynamics differ quite significantly from a
natural heart valve. Considering all these drawbacks to the mechanical valves,
their most important criteria is their durability. Although it can be done, re-
operation is not a preferable option, therefore, selecting a tissue valve for a
younger patient as the prosthesis of choice is usually denied. Similarly to the
tissue valve, mechanical valves are a mature design, and any significant
increase in either the tissue or mechanical heart valves effectiveness is highly
unlikely. Mechanical valves have roughly twice the amount of years of
operational service as compared to tissue valves. "Structural failure of approved
valves is almost nonexistent, and valves can reasonably be expected to perform
properly for at least 20 years. Anticoagulation with warfarin sodium is mandatory
at present. If the level of anticoagulation is maintained at appropriate levels, the
rate of valve thrombosis is low (0.0 to 0.3 events/100 patient-years)." [Sapirstein]
During 0968, the engineers that helped to develop the first Starr-Edwards
heart valve described the "nine commandments" that they used to help guide
them through their development cycle. The nine commandments focus on the
following characteristics, which they deemed to be of high concern, these
commandments are an excellent basis for a heart valve designer to follow.
0. 	 Embolism Prevention,
13
2. Durability,
3. Ease and Security of Attachment,
4. Preservation of Surrounding Tissue Function,
5. Reduction of Turbulence
6. Reduction of Blood Trauma
7. Reduction of noise
8. Use of Materials Compatible with Blood and Tissue,
9. Development of Methods and Sterilization
[Matthews]
The materials used in a mechanical heart valve are selected primarily for
their non-thrombogenecity and or high strength. During early heart valve
development some of these materials like Silicone or Teflon were selected
primarily for their bio-inert ability. However, as time has passed people realize
that these materials although not thrombogenic, do cause infections and or
develop scar tissue, which ultimately can end in thrombosis. Table 2.2 details
commonly used materials in mechanical heart valves.
14
2.4 Proposed design
As previously mentioned in the introduction, the new proposed design is to
construct a heart valve from a biodegradable scaffold. The scaffold after being
seeded with cells would be placed inside a bioreactor for the growth period. To
develop Acellular tissue, a scaffold is needed, this scaffold provides a foundation
for the cells. After a sufficient quantity of cells have been attached to the scaffold,
a process begins whereby the ratio of polymer scaffold to endothelial cells
decreases, in the end leaving only cells. During the formation, deposition, and
organization of the newly generated matrix, the scaffold is either degraded or
metabolized, eventually leaving a vital organ or tissue in place. During this
physical shift, it is necessary that the scaffold provide the strength, and elasticity,
needed during the timeframe where the model is mostly scaffold. It is believed,
that cells that are created during this time period, need to be exposed to process
parameters, similar to those seen in the tissue being duplicated. This process
equivalency will result in the organs being closer in terms of physical
characteristics to their natural component. "By seeding cells onto a porous valve
like scaffold and subjecting the seeded scaffold construct to conditions in the
incubator similar to those inside the heart, the researchers were able to produce
functional tissue engineered heart valves." [Applied Genetic News] Also, "Recent
work with cartilage and blood vessels indicates that applied shear stress has a
beneficial effect on the quality and quantity of the generated tissue. Blood
vessels grown with a well defined shear stress showed a higher content of
myosin heavy chains, a higher burst strength, higher collagen content, improved
15
suture retention, and better morphologic appearance than vessels obtained
under non-pulsed culturing." [Stock] Not only must the scaffold material have the
necessary physical characteristics to promote proper cellular growth, but it also
must be biocompatible and "meet both nutritional and biological needs for the
specific cell population involved in tissue formation." [Stock]
The cells used in any tissue engineering model need to be native to the
organ that is being mimicked, the native cell for the heart valve is the endothelial
cell. Endothelial cells are the same type of cell that comprises arteries and veins,
although they do not have the same physical properties, e.g. burst strength, wall
thickness. Studies are currently being done to determine if these sites can be
used for replication purposes. Since a direct biopsy for either a heart valve or
main artery is not practical, an alternate site must be selected, and in this case, a
peripheral vein may be acceptable. It has also been seen where dermal
fibroblasts have been used during cellular replication. "The cellular component of
normal heart valve tissue is composed mainly of endothelial cells and
myofibroblasts. Therefore, tissue for cell harvesting and in vitro expanding can be
obtained from vascular structures that contain similar cell components. Based on
this consideration, we used human aortic myofibroblast in the present study."
[Zund] Another option is to use Stem cells, these cells have the ability to rapidly
proliferate and differentiate into a wide variety of cells found in the human body.
Once the cells have been harvested and placed in the growth medium, a certain
amount of knowledge must be ascertained with regards to the control of
differentiation and cellular proliferation. If the cellular growth is not controlled
16
during this process, then the valve will not have the correct physical appearance
and its physical characteristics will not be representative of a native valve. Unlike
many of the organs found in the body, heart valves do not need a micro-vascular
system to obtain their nutrients and rid themselves of their waste. Heart valves
receive their nutrients by way of diffusion, which avoids a major technical
obstacle that faces many tissue engineers today, the creation of a micro-vascular
system. Any scaffold material selected for this project would need to satisfy a
variety of criteria's, which are detailed below:
1. Biocompatibility
2. Biodegradable, controlled erosion process
3. High cellular attachment strength
4. Physical properties, i.e. elasticity, tensile strength similar to heart valves
Work has already been done in creating scaffold materials that could fill
these characteristics; they have been used in either heart valve or vascular
tissue engineering projects. Dr. Simon Hoerstrup and his colleagues of the
Harvard Medical School are working diligently on developing a Tissue
Engineered Heart Valve. This group has developed a unique process whereby
they can create a three dimensional heart valve scaffold, via a Stereolithography
melt forming process. The material that this group has chosen for their scaffold is
a poly-4-hydroxybutyrate (P4HB) (Tepha Inc., Cambridge, Ma), "P4HB is a
semicrystalline, thermoplastic elastomer with a melting point of approximately
60C and a glass transition temperature of —51C." [Sodian] This material has
worked very well, "The heart valves were tested in a pulsatile bioreactor, and it
17
was noted that the leaflets opened an closed synchronously under sub-
physiological and supra-physiological flow conditions." [Sodian] Since the
proposed design is structured around the concept of a biodegrading material
then an explanation of the degradation cycle of PLA may be needed. 'Water
penetrates the bulk of the material, usually attacking the chemical bonds in the
amorphous phase and converting long polymer chains into shorter water soluble
fragments. Because this occurs in the amorphous phase initially, there is a
reduction in molecular weight without a loss in physical properties, since the
device matrix is still held together by the crystalline regions. The reduction in
molecular weight is soon followed by a reduction in physical properties as water
begins to fragment the device. In the second phase, enzymatic attack and
metabolization of the fragments occurs, resulting in a rapid loss of polymer mass.
This type of degradation when the rate at which water penetrates the device
exceeds that at which the polymer is converted into water-soluble materials
(resulting in erosion throughout the device) is called bulk erosion. All of the
commercially available synthetic devices degrade by bulk erosion." [Applied
Genetics News]
■ Polyglycolic-acid (PGA)
The first synthetic absorbable suture, it was the first bio-polymer used in the
successful creation of a new tissue, it is a highly crystalline material, with a high
melting point. PGA looses about 50% of its strength after two weeks and 100%
after four weeks it is completely absorbed in 4 — 6 months.
■
	 Polylactid-acid (PLA)
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Poly(dl-lactide) DLPLA is an amorphous material, it has a low tensile strength
high elongation and a rapid degradation time, used frequently as a drug delivery
system.
■ PGLA
A 90/10 copolymer of PGA and PLA, has been used successfully in a heart valve
leaflet substitution experiment.
■ Hydrogels
Hydrogels are used mostly in drug delivery devices, change physical states from
a liquid to a gel during implantation.
■ Poly-3-hydoxybutyrate and Poly-3-hydoxybutyrate
Poly-3-hydoxybutyrate has a high elasticity and the ability to control its
degradation rate, not much is known about Poly-3-hydoxybutyrate however its
physical properties should be fairly close to Poly-3-hydoxybutyrate.
■ Polyhydroxyoctanoate (PHO)
Presently this material is being developed by Tepha Inc. and studied by Dr. Ralf
Sodian's of the Harvard Medical School. It is biodegradable and believed to have
good elastic properties.
■PHA4400
A strong and flexible material, has been successfully used as a bio-absorbable
material, the material used during Dr. Simon Hoerstrup's heart valve
experiments.
Ideally, one of the materials listed above could be used in this project, the
scaffold design could be simply an exact duplicate of a human heart valve. The
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valve would perhaps have a sewing ring attached to it, which would give the
bioreactor a place to hold the valve during growth and also give the surgeon an
area to suture during surgery. During the growth process the bioreactor pressure
gradient and flow rate would need to be investigated as well as the materials rate
of degradation and the amount of growth media used. Thus in conclusion, the
ideal tissue engineered heart valve would be comprised of the patient's own
cells, have physical properties similar to a native Heart valve and have a short
Bioreactor growth period.
2.5 Conclusions from literature review
People are living longer these days, unlike 50 years ago it is not uncommon to
see many people live beyond their 70'th birthday. Coinciding with this extended
life span is a desire by many people to be able to live the life that they did when
they were 50 while they are 70. This cannot be done with the biomedical
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prosthesis available today, the devices available today only have a ten to fifteen
year lifespan. A large majority of people begin having major surgery when they
reach their mid to late 50's, so by the time they reach their mid 70's their medical
prosthesis are at the end of their lifespan. Surgery to remove these types of
devices is almost impossible, taking into consideration their age and their
debilitating health condition. Therefore, a change needs to be made if society is
going to reach the next plateau in life expectancy. Permanent organ and tissue
replacements need to be developed that will perform equivalent to the original
tissue or organ being replaced. The proposal being recommended in this thesis
is just such a device, if successful could meet all of these requirements.
There are many issues that need to be addressed to develop a Tissue
Engineered Heart Valve, such as: selecting the correct material, determining the
correct Bioreactor process conditions, controlled tissue growth, achieving high
cellular attachment strength, uniform dimensional geometry of the scaffold,
developing the scaffold manufacturing process, and many others.
In the literature review, the proposed design discusses the finished
product being a representative physiologically valve, for this thesis however the
author will devote his time to the selection of a material, the processing of the
samples, and the subsequent physical testing. There will be no cellular growth
development with these scaffolds or degradation studies. If this thesis was
brought any further beyond this initial work, those area's and others would be
investigated thoroughly. The next step to be taken is to develop a test protocol,
which will detail the material to be used, and a testing procedure. The materials
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selected for this study will most likely be selected from the list of materials
detailed in table 2.3. The test procedure will be an attempt at developing a test
format to be used to characterize the physical properties of the scaffold
materials. Therefore, in conclusion the test sample design for this study will be a
flapping hinge design instead of an actual heart valve.
CHAPTER 3
RESEARCH OBJECTIVE
For the remainder of this thesis, the body of the report will deal with the work that
went into the development of the scaffold manufacturing process, the final
process used in making the samples, and the testing that was done to fully
characterize the scaffolds. The material selected for the scaffold development is
Poly-Lactic-Acid (material samples provided by Johnson & Johnson), this
material was selected for its ability to meet several of the design requirements
listed in the previous sections. Poly-Lactic Acid (PLA), is a biodegradable
polymer that has the processing flexibility needed to achieve satisfactory results.
Other materials mentioned in the literature review may have lower tensile
strength properties and higher ductility, possibly making them a more appropriate
candidate, however those companies did not make their materials available for
this study.
Since PLA does not have the flexibility needed for a tissue scaffold,
modifications were made to the material in an attempt to increase its flexibility.
Compounding Bovine Collagen with PLA as well as creating a porous structure
using NaCI was used. The high ductility of collagen when combined with the PLA
will translate to a lower overall tensile strength. NaCI, was added to create a
porous structure in the scaffold, this would accomplish two things, one decrease
the tensile strength of the scaffold and secondly create sites available for cellular
attachment.
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CHAPTER 4
MATERIAL DEVELOPMENT
4.1 Process development
During the early parts of the research, it was discovered that there are two ways
of processing PLA, the polymer chosen as the material to be used in this study.
Those two ways are solvent casting and heat forming, the latter was attempted
early on, however, it became rapidly apparent that it would be difficult and costly
to develop. Using the heat forming method would remove process flexibility from
the material compounding process. Therefore, the solvent casting was selected
for the following reasons, it is easy to modify, inexpensive to produce samples,
and lastly, it offers flexibility during the compounding process.
Once the decision was made to process the scaffold samples via solvent
casting, a series of rapid experiments were conducted to determine the optimum
parameters and methods. The mold designed to make the initial prototype
samples was a three dimensional model that was made to resemble a working
valve. Potential solvents were examined to determine which solvent would most
aggressively dissolve PLA, i.e. alcohol, Hexane, Methanol, and eventually
Methylene Chloride, which was found to work the best.
During this initial period prior to making the final scaffold samples, an
enormous amount of information was gathered about the intracies of processing.
These areas will be discussed in more detail below, however for now they are
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listed as: Scaffold Geometry, Scaffold Homogeneity, Solvent evaporation, and
Preparation of the PLA Gel.
3.2 Scaffold geometry
The geometry of the scaffold both the thickness and the profile are dependent on
processing conditions and illustrated clearly in the test results. The initial
prototype sample,
shown below in
figure 2.5 was
designed 	 to
imitate a valve,
not an actual
heart valve, but a
two way leaflet
valve. It was difficult to control the geometry of this valve due to the overall
thickness of the valve and the varying rate of solvent evaporation. During the
evaporation period the solvent will evaporate from the scaffold in some areas
faster than in others, thus causing large voids to occur in the scaffold. Also, due
to the solvent being present during this period, there is a large amount of
shrinkage that needs to be taken into consideration. During the time that the
three dimensional mold was being used, a hurdle was reached, after the PLA gel
was injected into the mold, how would it be separated without damaging the
geometry of the part? Introducing a step whereby after the gel had been injected
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into the mold, it was immersed in a liquid Nitrogen bath to freeze the Methylene
Chloride solved this, after several minutes at —190F the mold sample is easily
removed. The sample is then placed in a environmental hood for solvent
evaporation. After the sample has been removed from the environmental hood it
is removed from the mold, due to the significant difference in thermal expansion
between steel and the PLA scaffold it is easily removed from the mold.
4.3 Scaffold homogeneity
The most desirable characteristic of each valve scaffold would be reproducible
scaffold samples with uniform cross sections, absent of voids or foreign matter.
The voids are created due to air bubbles created during the PLA gel preparation
period, during the solvent evaporation period sections would collapse and leave
craters in their place. Objects that may be present in the scaffold could be either
foreign matter captured during the processing period or fragments of PLA resin,
not fully dissolved during the solvent dissolution period.
4.4 Solvent evaporation
Once the PLA resin has been combined with the Methylene Chloride, mixed
thoroughly and formed into the desired shape it must be placed into a vacuum
oven in order to remove the solvent. For a valve to be made using this process
method, the solvent must be entirely removed from the scaffold. TGA testing has
been done to determine the proper oven temperature, and drying time, to be
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used to fully remove the solvent from the samples. The results from that testing
will be discussed in full detail in the results section.
4.5 Preparation of the PLA gel
In the beginning of the PLA solvent dissolution development the resin was simply
added with solvent and mixed thoroughly, and then more solvent was added to
the compound until the resin was deemed to be in gel form. This process takes
time and consumes a large amount of solvent. A preliminary step was added to
the process whereby the resin is crushed, until it is in the form of a fine powder,
thus increasing the PLA surface area and increasing the rate of dissolution. Now
by using the PLA in a powder form during the solvent process, takes a fraction of
the time, and reduces the amount of solvent needed significantly.
4.6 Solvent injection molding
After several attempts to mold scaffold samples, the process was found to work
well, after the top plate of the mold was removed, the exposed sample looked
acceptable. However, over time the sample would deform and the top portion of
the scaffold would change dimensionally. At this point it was determined that to
construct a useful three dimensional scaffold, the thickness of the scaffold must
be at a minimum. The top section of the thickened scaffold, since it was exposed
to the air, would loose solvent first and then voids left by the solvent would
collapse and form an uneven landscape on the top portion of the valve. Detailed
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below is a description of the procedure that was used during the initial scaffold
preparation for use with the three dimensional mold.
1. The resin is weighed out to the specified amount and placed in a beaker.
2. The specified amount of solvent (Methylene Chloride) is added to the
beaker.
3. The resin/solvent solution is covered while inside of the beaker and allowed
to sit for several hours to allow the resin to fully dissolve in the solvent.
4. The gel (resin/solvent) is mixed aggressively until it is homogenous.
5. The gel is poured from the beaker into a 2 oz. Syringe, evacuating the air
from the syringe and forcing the gel to the Luer tip, a tip cap should be used to
cover the luer tip.
6. The 2-piece mold is assembled and the screws holding the mold together
are hand tightened, (if the screws are tightened too much they will become very
difficult to be removed after the freezing step).
7. The syringe luer is inserted into the mold entry port and the gel is injected
into the mold by actuating the plunger rod.
8. After the mold has been filled with the solution, it can then be immersed in
the liquid Nitrogen bath for several minutes.
9. Once the mold has been removed from the liquid Nitrogen bath it should be
immediately separated (protective gloves should be worn when removing the
mold from the bath) thus keeping the sample in one piece.
10. Place the sample, present in only one portion of the mold into the
environmental hood and let sit for 23 hours to let the solvent evaporate.
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11. Remove the sample from the mold once it has been totally dried of the
solvent.
4.7 Solvent cast molding
Taking the lessons learned from the initial mold, a second mold was created; this
mold was much simpler and designed to create thinner prototypes that could
enable the molded material to be more flexible (same modulus less volume).
Another lesson learned was that instead of just one prototype made from one
batch of solution, the new mold had five cavities so an entire group of samples
can be made and tested from one batch. Similarly, as was done with the initial
polymer process, resin will be dissolved in Methylene Chloride. However, there is
no need to inject into a mold, these samples will be simply poured into their
individual cavities and evenly dispersed throughout the cavity. With the injection
molding process samples were produced that accurately portray a valve.
However, to learn more about the materials, the casting method can be used.
The new solvent casting method is detailed below:
1. The resin is weighed out to the specified amount and placed in a beaker.
2. The specified amount of solvent (Methylene Chloride) is added to the
beaker.
3. The resin/solvent solution is covered while inside of the beaker and allowed
to sit for several hours to allow the resin to fully dissolve in the solvent.
4. The gel (resin/solvent) is mixed aggressively until it is homogenous.
29
5. The gel is poured from the beaker into a 2 oz. Syringe, evacuating the air
from the syringe and forcing the gel to the Luer tip, a tip cap should be used to
cover the luer tip.
6. Using the syringe, the material is injected onto the cavity, and then the
material is rolled into the cavity, whereby flattening the material and filling up the
cavity at the same time.
7. Once the material has been formed into all of the cavities, the plate is
transferred to the drying oven for the solvent evaporation period.
8. After 3 hours of drying the samples in the oven, it can be removed and
placed into their identification bags.
CHAPTER 5
DESIGN ANALYSIS AND TEST PROTOCOL
As mentioned in the previous pages, the ideal heart valve must be as strong and
flexible as a natural heart valve, and degrade in a controlled manner while
allowing steady cellular attachment with strong adhesion. Two separate concepts
have been incorporated into this study, in a attempt to meet two of the previously
mentioned ideal scaffold characteristics. Those two characteristics are controlled
flexibility for extended periods of time, and increased cellular attachment
strength. The two concepts being investigated in this thesis are; Developing a
porous structure via a Sodium Chloride leaching, and the compounding of Bovine
Collagen with the PLA to increase flexibility and fatigue life.
5.1 Scaffold porosity and degradation rate
The polymer to pore ratio would be varied during any further investigation, low,
medium, and high distributions. Preliminary studies, have already given some
insight into the effect of pores on the polymers ability to degrade and physical
characteristics during the degradation period. Studies have shown that PLA and
PGA materials degrade via Bulk degradation method, also that as the amount of
pores are increased in the polymer that the degradation time will increase. The
physical strength of the polymer will decrease as the amount of pores is
increased. Recent studies have shown that polymers exposed to flow during the
cellular attachment period, rather than static conditions culturing process results
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in a longer degradation time period. "The hydrolysis of PLA-PGA materials is
catalyzed by the presence of a high concentration of carboxylic end-groups; thus
the degradation products of PLA-PGA materials serve as catalysts for the
reaction." Therefore if these degradation products are not removed from the
bioreactor during operation then the breakdown of the polymer will be
accelerated. "Thus, the mass, molecular weight and elastic modulus data clearly
indicate that PLA-PGA scaffolds degrade faster when they are less
porous/permeable and when they are not subjected to fluid flow." [Agrawal] With
regards to polymers exposed to cyclic flow another variable that must be
investigated during this process is whether the fluid is turbulent or laminar while it
is in contact with the scaffold. The state of the fluid (turbulent or laminar) will
almost certainly have an effect on the degradation kinetics of the material as well
as the cells during their attachment process.
Previous research has shown that pore distribution as well as size will
have a dramatic effect on both the ductility and degradation time of the scaffold.
The environment inside of the bioreactor will necessitate a ductile material that
can oscillate repeatedly, however the degradation time needs to be minimal,
such that cell growth can replace the scaffold without causing a bulking of the
composite (polymer scaffold/cellular tissue).
As the scaffold is oscillating under a specified pressure and flow inside the
bioreactor the endothelial cells will be attaching themselves to the surface.
Recent work has shown that the pressure and flow that the endothelial cells are
exposed to during this attachment process will dictate the strength and
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orientation of the attached cells. To aid in the attachment process of the
endothelial cells a porous structure will be created in the valve. The distribution
and concentration of the pores and their size will be crucial for the cellular
attachment period since unlike with collagen synthetic polymers do not have
natural binding sites.
The most widely used natural polymer is collagen and the most widely
used synthetic polymer is PGA, PLA or PLGA. The characteristics being
investigated are the modulus of elasticity and the flexural strength. These
components of the material will dictate how successful they will be during the
cyclic loading. The modulus of elasticity testing will relate how well the material
will oscillate, and the flexural strength will determine the force needed to oscillate
the valve.
5.2 Protein and cellular seeding process
The process of the endothelial cells attaching themselves to the biodegradable
polymer is an intricate process whereby to be successful several areas need to
be properly investigated. These areas include the following; growth factors,
scaffold pore structure, protein and cellular seeding, and bioreactor design and
operation. "Research suggests that the initial adhesion of smooth muscle cells to
these polymers is mediated by both fibronectin and vitronectin binding, but over
time (23hr), cellular adhesion is primarily mediated by binding to vitronectin."
[Nikolovski] Vitronectin is the primary protein seen with synthetic polymers,
however both fibronectin and vitronectin have been observed to attach
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themselves to natural polymers (collagen). The determining factor as to the
effectiveness of the completed valve, will be determined by the cellular
orientation and strength of the scaffold.
Cellular attachment strength is dependent upon the following protein
seeding, polymer pore structure, biomaterial surface activity and biological
growth factors. Synthetic polymers do not have natural binding sites therefore
protein attachment is vital to the overall process since they will provide the only
attachment points for the cells. During the growth cycle cellular orientation is
primarily due to the flow cycle seen in the Bioreactor. Prior to cellular seeding the
scaffolds should be bathed in an extra cellular matrix with selected proteins
present, these proteins will adsorb to the surface and provide the necessary
attachment junctions. Once proteins have adsorbed and the cells have attached
themselves to the proteins (integrins attach themselves to the proteins and link
themselves to the endothelial cells) growth factors will be introduced to
accelerate the growth cycle.
5.3 Test protocol
5.3.1 Background
In the beginning of the thesis a introduction to the heart valve device field was
given, including a discussion of the evolution of the mechanical heart valve, as
well as devices both mechanical & tissue currently used in the market. Then the
goal of this research was stated, a biodegradable polymer used for a heart valve
scaffold. The next sections covered were the background information on the
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development of the scaffold manufacturing process, as well the introduction to
the chosen material, PLA. Therefore now that the heart valve field has been
introduced, the materials have been discussed, and the process has been fully
explained, it is time to discuss the next to last section, testing. The test protocol
being discussed below is a testing regimen the author believes will help in
characterizing the chemical and physical properties that are vital to a
successfully operating heart valve scaffold.
5.3.2 Objective:
The objective of this protocol is to determine through physical and chemistry
testing the physical characteristics of each material. These tests are being used
to identify the best possible candidate to be used for a tissue engineered heart
valve scaffold.
5.3.3 Test Supplies and Equipment
1. Poly-L-Lactide, PURAC, biochem
2. Bovine Fibrillar Collagen, Datascope, Collagen Products Division
3. Methylene Chloride, Sigma
4. Ethylene Glycol, Sigma
5. Sodium Chloride, + 80 mesh, ALDRICH
6. 50m1 Glass Beaker, Kimax
7. Aluminum Scaffold Casting Plate
8. 2 oz. Plastic Syringe, Becton Dickinson
9. 2 inch wide Parafilm, American National Can
10. Stabil Therm Electric Vacuum Oven, BLUE M, General Signal
11. Stainless Steel Stirring Spoon
12. Instron test stand, Tensile/Compression model # 5563
5.3.4 Sample Description
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5.3.5 Procedure
Four out of the five scaffold materials, detailed above in Table 5.1, will be made
using the solvent casting method detailed previously in section 3.7. One of the
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objectives of this study is to determine the amount of solvent needed to fully
dissolve Poly-Lactic-Acid.
5.3.6 Test descriptions
1. Flexural testing, to determine the force necessary to bend the scaffold as
it would be done in a bioreactor.
2. Cycle testing, To obtain qualitative visualization of the scaffold in
operation. It needs to be determined whether the material in question can
successfully operate without fracturing during operation, and if fracturing does
occur how many cycles. Scaffold samples will be immersed in a heated solution
during the testing. The scaffold will be held rigidly at one end while a load is
being applied repeatedly to the other end of the scaffold. The load will be applied
at a rate of 6Oin/min with a total displacement of 1lin, for 6O cycles.
3. Tensile testing, to determine the tensile strength of the material in
question. Test samples will be uniformly prepared in a simple rectangular shape,
such that they can be easily tested in a tensile testing machine. The samples will
be inserted into the machine such that both ends are held securely at both ends.
Upon activation the machine will pull the sample in tension to its breakage point,
at a rate of 1lin/min.
4.FAIR, (Fourier Transform Infrared Spectroscopy), to determine the
chemical composition of the material in question.
5. 	 SEM, to photograph the material under high magnification to characterize
the pore structure and overall architecture of each material.
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6. TGA, (Thermo gravimetric Analyzer) measures the change in mass as a
function of temperature under a controlled atmosphere. The TGA can be used to
analyze de-absorption and decomposition behavior and characterize oxidation
behavior. The TGA may be used to characterize phenomena such as
evaporation and drying, decomposition, oxidation, and oxidative stability. Its
principal uses include measurement of a material's thermal stability and
composition.
7. DSC, (Differential Scanning Calorimeter) measures the amount of energy
(heat) absorbed or released by a sample as it is heated, cooled, or held at a
constant temperature. Typical applications include determination of melting point
temperature and the heat of melting; measurement of the glass transition
temperature; curing and crystallization studies; and identification of phase
transformations.
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Table 5.3 Scaffold Flexu ral Test Results
Group
Maximum Bending Force
(lbf)
Load at 0.25"
(lbf)
Load at 0.5"
(lbf)
A 0.049 0.036 0.049
A 0.143 0.099 0.143
A 0.057 0.044 0.056
C 0.008 0.007 0.004
C 0.014 0.014 0.006
C 0.012 0.009 0.010
D 0.164 0.119 0.164
D 0.226 0.166 0.225
D 0.153 0.108 0.153
E 0.210 0.150 0.210
E 0.147 0.088 0.147
E 0.330 0.234 0.330
Figure 5.1 Diagram of the scaffold flex testing
setup.
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5.5 Discussion of results
At the beginning of this study, the goal set forth was to identify a material that
could be used as a biodegradable scaffold for the use in a Heart Valve
Bioreactor. The physical and chemical results obtained through testing, illustrates
the need, for further development with these materials. Using Poly-Lactic-Acid
and Bovine Collagen simultaneously offers several benefits, optimal physical
characteristics as well as superior cellular attachment strength — a characteristic
not tested in this thesis.
5.5.1 Tensile testing
The tensile test results are located in table 5.2, the testing was conducted on a
Instron test stand and the samples (dry and at room temperature) were pulled in
tension until failure at a rate of 1"/min. The Ultimate Tensile Strength (UTS) of the
PLA, both groups A and E are much greater than that of a Heart Valve's UTS,
although they have a much lower % elongation. The fortunate case with the PLA
having such a high UTS is, that when the thickness of the Scaffold drops even
lower than previously tested, it will still be able to function adequately. The UTS
of the PLA/NaCI scaffold seems to have been effected from the porous structure
created by the NaCI, its tensile strength and Young's Modulus are similar to the
Heart Valve omitting the elongation property. When combined with the PLA, the
collagen did show to have an effect on the Tensile Strength, therefore, while
adding cellular recognition sites, the collagen when combined with PLA can
provide needed flexibility.
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5.5.2 Scaffold Flex Testing
The Scaffold Flex test results are located in table 5.3, the testing was conducted
on a Instron test stand, (testing apparatus is detailed in figure 5.1) the samples
(dry and at room temperature) were deflected at a rate of 10"/min for a distance
of 0.5in. The bending force was on the high side for nearly all three groups,
exception being the Bovine Collagen group. A problem seen with the Collagen
group was, that the reaction force to the bending force was not seen to be
substantive. The collagen samples were very weak and offered very little
resistive force when deflected. For a scaffold to be successful this reaction force,
must be inherent in the material such that, after the scaffold has been flexed it
will quickly recover to its original position.
5.5.3 Valve Cycle Testing
The cycle test results are located in appendix A; the samples were immersed in
heated water and tested in the same apparatus as in the flex testing. The load
was applied to the scaffold at a rate of 60in/min, and the load was applied for a
distance of one inch. Therefore, since it took one second to displace the valve,
and one second to return to its resting place, the total cycle test lasted for two
seconds. The scaffold cycle in this thesis operated at a rate of 30 cycles/minute,
a normal heart valve will operate at a rate of 75 cycles/minute, therefore, more
testing is needed at a higher cycle rate.
Assuming a physiological pressure at the valve of 13Omm/Hg, and a cross
sectional area of 0.169in 2 (diameter based on a 31mm St. Jude Bi-Leaflet
prosthesis) then the force applied to open the valve during the cardiac cycle will
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be roughly 3.168lbs. Cycle testing would need to be done as a benchmark on
actual heart valves, to determine the range of force seen during normal
operation. This force cannot be too high or it would restrict blood flow, too low
and the valve will not stay closed while the ventricle is filling. During the cycle
testing, the scaffold showed no signs of fracturing or stress. The collagen on the
PLA did however, begin to separate from the PLA while in the warm solution. The
PLA when exposed to the cycle testing performed adequately, even though the
samples were not at their optimum thickness, or appearance. The cycle testing
done in this thesis, is a preliminary feasibility study, and was focused on
determining the ability of the scaffold to cycle, over a short time period. More
cycle testing would need to be done, for longer time periods, at higher cycling
rates, and under bio-relevant conditions.
5.5.4 TGA testing
The TGA test results are located in Appendix B, there are eleven TGA graphs
attached in this appendix. The objective of conducting TGA tests on the material
was, to determine if the solvent used during the manufacturing process stayed in
the scaffold, after 0.5, 0.5, 2.5, and 3.O hours of drying in a vacuum oven, at an
elevated temperature (6OC). The table shown below, listed as Table 5.3 lists the
temperatures for selected points on a TGA curve for the three groups (A, B, &
Control) which represent three different PLA/solvent ratios, (50%, 30%, and O%).
The points identified in figure 5.3 represent distinct points, in the curve that
characterize specific areas in the TGA test cycle.
The TGA testing of the PLA samples (Group A & B) revealed that the
solvent still resides within the material. The point C for groups A & B was fairly
consistent with each other, but quite different from the unadulterated resin. This
shows that the amount of solvent used during the manufacturing process is
inconsequential. Regardless of the amount of solvent used during the process,
both groups showed to have roughly 0.5 — 2.O% of the material being solvent.
The drying process did not seem to have an effect on the material; there was no
significant difference between 3 hrs. of drying and 1.5hrs. of drying. The curve for
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the PLA resin is very smooth and shows no scatter during the test, the same
cannot be said of groups A & B. After point B the curve for groups A and B
bounces up and down for a short time period, and then eventually straighten out.
As the material reaches 100°C the material begins to melt, which is occurring
before the melting point of PLA. Both these characteristics are evident in both
groups A & B and are evidence of the methylene chloride boiling out of the PLA,
during the TGA test cycle.
5.5.5 DSC testing
The DSC test results are located in Appendix C, there are three graphs attached
in Appendix C, which are Unadulterated PLA, PLA/Collagen, and PLA/NaCl. The
results obtained during the DSC testing, come to the same conclusion reached
during the TGA testing, which is, solvent still resides in the scaffold. The solvent
seems to be removed from the material roughly in the temperature range of 100
— 15OC. The bimodal peaks in the PLA/Collagen and PLA/NaCI curves represent
a reorganization of the crystalline structure during the heating process. Both PLA
scaffold materials tested, showed a low level of crystalline regions in the polymer
structure.
5.5.6 FTIR & SEM testing
The FTlR test results located in Appendix D were done to identify the chemical
structure of the scaffolds. The FTlR curves for the following groups: PLA,
PLA/NaCl, & PLA/Collagen had almost identical peaks. There was however, an
increased amount of small absorbance scatter seen in the PLA/NaCl and
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PLA/Collagen samples between 3000 — 2000cm -1 wavenumbers, as compared to
the control. The pure Collagen group had a more unique curve which shows a
large and wide peak around 3700 — 2700 wavenumbers, this peak although small
is visible with the PLA/Collagen group. The PLA/NaCI group is nearly identical to
the pure PLA group, indicating that there was little to no NaCI left over from the
processing procedure.
The SEM picture located in Appendix E is a high magnification picture of
the PLA/Collagen scaffold surface. As hoped during the design of the materials
the scaffold has large peaks and valleys, which during the cellular growth
process would provide excellent adhesion points. The next step would be to
increase the distribution and orientation of the collagen throughout the scaffold.
The PLA/NaCl sample was unable to be identified under the SEM, however,
further development of the porous structure, including increased pore size and
quantity is needed.
CHAPTER 6
CONCLUSIONS AND SUGGESTIONS
6.1 Issues with present material
The samples made for this Thesis were shown to have adequate physical
properties, high physical strength but low elongation. It is believed that for a
scaffold to be successful it must behave similarly to a more ductile material, e.g.
Latex, Silicone. Assuming a heart rate of 75 beats/minute, then an average heart
valve will cycle 108,000 times in one day. Currently the only material that can
withstand that workload for as long as say fifty years is an individual's own heart
valve tissue. This material can last that long because it is constantly regenerating
itself, therefore, the requirement of the scaffold studied in this thesis is too last
long enough for the living tissue to take over.
The PLA samples made during this study were done using a solvent, it
was found from TGA and DSC testing 0.5 — 2.O% of the material is methylene
chloride. This last amount of solvent still present in the material may prove to be
very difficult to remove, in fact the only way to decrease or remove it may be in
reducing the thickness of the scaffold as previously discussed. As was seen in
the DSC testing, the morphology of the material is not uniform, which is
undesirable, random crystalline segments reside within the polymer. Therefore,
while the test results look promising and many obstacles have been overcome,
there are two major obstacles that need to be surpassed. The first obstacle is to
determine, whether or not the scaffold can survive the cycle load, long enough
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for it to be replaced by living tissue, if not, then what modifications to the material
can be made to enable it to survive. The second obstacle, is to determine if the
solvent can be removed from the material, perhaps it can be accomplished with a
thinner scaffold dried over a longer time period at lower temperatures. Whatever
the method is, the solvent must be removed from the material, a material cannot
be used as a tissue scaffold in a medical procedure if it contains methylene
chloride. The author believes that these two issues are the primary obstacles
facing any further development of PLA as a heart valve tissue scaffold, however,
several methods mentioned in this thesis, and listed again below, can be used to
solve these design issues.
6.2 Solutions to issues
Detailed below are possible solutions to the design issues mentioned in the
previous section, which again are improving the flexibility of the scaffold, and
removing solvent from the material.
1. lmprove the geometry of the scaffold samples. By better controlling and
improving the manufacturing process the cross section will be more
uniform throughout the sample. Another improvement to the geometry
would be to further decrease the thickness, possibly in the range of
0.010 — 0.020inches.
2. Further develop the scaffold compounding process. The collagen and
NaCl seem to have had a beneficial effect on the physical strength of the
scaffold. lt is already known from literature sources, that collagen is a
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beneficial component during the cellular attachment and orientation
process. The amount of NaCI used in the study can be increased and
the process should be developed further. These two components,
collagen and NaCl, can both increase the flexibility of the material while
also helping during the growth process.
3. lmprove the post Scaffold molding process. After the samples have been
molded they are placed into a vacuum oven and raised to an elevated
temperature. This drying process, used to eliminate the solvent from the
scaffold, has not worked. More process development is needed here to
determine, if this last remaining amount of solvent can be removed from
the material. Options that may be successful could be any of the
following: increased drying times, bathing in water post processing,
change of solvent, introduction of heat during the molding process, and
finally, further reduction in the scaffold thickness.
6.3 Possible future development
In this Thesis the author has touched upon three key areas for any successful
Tissue Engineering Scaffold, porosity, flexibility, and dimensionally accurate.
Test results collected from this research has shown, that using a porous PLA in
combination with collagen can provide to be a successful heart valve scaffold.
Preliminary testing has been helpful however; a more detailed setup for both the
flex and cycle testing is needed. The tests need to be refined in their handling of
the samples, as well as incorporating bio-relevant attributes to them.
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The solvent injection molding process used early in the process
development needs to be re-investigated. The solvent injection process can
create three dimensional scaffolds, which are necessary for any further scaffold
development. With the advancements made during the process development
cycle such as, refinement of the resin, reduction in solvent, and incorporating
thinner, more uniform cross sections, it is possible that the solvent injection
molding process may be used.
As the material is being further developed as mentioned previously, work
must begin on the cellular growth process. There needs to be a study done to
determine the cellular attachment strength and orientation with the PLA scaffolds,
as well as extreme cycle testing to determine their fracture point. Therefore a
bioreactor would need to be designed to facilitate in the development of the
scaffold material. This bioreactor would need to provide the pressures, and flow
rates found in the chamber of the Heart, in order to grow endothelial cells in the
proper manner. A Bioreactor design being offered by the author is detailed in
Appendix F.
ln conclusion, the author believes that the possibility of developing a
biodegradable polymeric scaffold for a Heart Valve is great. The advancements
made in this thesis, have shown that it is possible to use PLA for just such a
purpose. More work is needed to develop a heart valve scaffold, however, the
groundwork has been established and a target has been set. lt is the author's
belief that if the development outlined in this thesis is continued, then a living
heart valve can, and will be created.
APPENDIX A
SCAFFOLD CYCLE TEST RESULTS
Cycle testing of the PLA/Collagen scaffold, sample was immersed in warm
solution and deflected 60 times over a two minute period.
Figure A.1 Valve cycling of PLA/Collagen scaffold, 120
second scale.
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Figure A.2 Valve cycling of PLA/Collagen scaffold, 60 second
scale.
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Figure A.3 Valve cycling of PLA/Collagen scaffold, 25 second
scale.
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APPENDIX B
TGA TEST RESULTS
TGA testing of PLA scaffold samples, this testing was done to determine the
amount of solvent still present in the material after the casting operation.
Figure B. 1 TGA testing of natural PLA resin.
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Figure B.2 TGA testing of (Group A) 0.5 hr dried solvent cured
PLA —scaffold.
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=figure B.3 TGA testing of (Group A) 1.5 hr dried solvent cured
'LA —scaffold.
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Figure B.4 TGA testing of (Group A) 2.5 hr dried solvent cured
PLA —scaffold.
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Figure B.5 TGA testing of (Group A) 4.0 hr dried solvent cure
PLA —scaffold.
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Figure B.6 TGA testing of (Group A) 4.0 hr dried solvent cured
PLA —scaffold.
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Figure B. 7 TGA testing of (Group A) 0.5 hr dried solvent cured
PLA —scaffold.
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Figure B. 8 TGA testing of (Group B) 0.5 hr dried solvent cured
PLA —scaffold.
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Figure B. 9 TGA testing of (Group B) 0.5 hr dried solvent cured
PLA —scaffold.
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Figure B. 10 TGA testing of (Group B) 0.5 hr dried solvent
cured PLA —scaffold.
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Figure B. 11 TGA testing of (Group B) 0.5 hr dried solvent
cured PLA —scaffold.
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APPENDIX C
DSC TEST RESULTS
DSC testing of PLA scaffold samples, this testing was done to determine if
solvent is still present, and also characterize the morphology of the material.
2
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Figure C.2 DSC testing of PLA/Collagen scaffold material.
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Figure C.3 DSC testing of PLA/NaCI scaffold material.
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APPENDIX D
FTIR TEST RESULTS
FTlR testing of scaffold samples from all four material groups, this testing was
conducted to determine the composition of each group.
68
Figure D.2 FTIR scan of solvent cured PLA/NaCI scaffold
material.
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Figure D.3 FTIR scan of solvent cured PLA/Collagen scaffold
material.
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Figure D.4 FTIR scan of solvent cured Collagen scaffold
material.
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Figure D.5 Combined FTIR scans for all four scaffold materials.
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APPENDIX E
SEM TEST RESULTS
SEM picture of PLA/Collagen sample, photograph was taken to visualize the
variable surface of the scaffold material.
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APPENDIX F
BlOREACTOR DESlGN
The diagram below is of the proposed heart valve bioreactor, it is designed to
cycle one
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